Investor Presentaiton
30,000
20,000
10,000
1-Jan-22
8-Jan-22
15-Jan-22
22-Jan-22
29-Jan-22
5-Feb-22
12-Feb-22
19-Feb-22
26-Feb-22
5-Mar-22
70,000
Pandemic Control Is Key To Strong Economy
INDONESIA'S COVID-19 CASES CONTINUE TO DECLINE
Activity Restriction (PPKM) - Delta Varian (June 2021):
■ Activity restriction level determination is rigorous
■Level 1 Maximum Capacity 75%, At Level 4 Many Activities Closed
■ Strict Operational Hour Restrictions
1.Vaccine Indovac
(Bio Farma)
DOMESTIC VACCINE DEVELOPMENT
60,000
50,000
40,000
Activity Restriction - Omicron SubVarian (January 2022):
■ Relaxation of level determination only uses community
transmission indicators
■ The maximum capacity at each level is adjusted.
■ Capacity at level 1 reaches 100%
Restrictions on operating hours are still in use.
.
EUA for primary vaccination (above 18 years old) have been
issued on 24th September 2022.
• 2022 Production: 20 million
•
.
•
Production Capacity: 98,4 million doses per year
EUL have been submitted to WHO on 7 September 2022
On Progress: EUA for booster above 18 years old, primary
for 12-17 years old, primary and booster for children 6-11
years old
12-Mar-22
19-Mar-22
26-Mar-22
Apr-22
9-Apr-22
16-Apr-22
23-Apr-22
30-Apr-22
7-May-22
14-May-22
21-May-22
28-May-22
4-Jun-22
11-Jun-22
18-Jun-22
25-Jun-22
2-Jul-22
9-Jul-22
16-Jul-22
23-Jul-22
30-Jul-22
6-Aug-22
-Aug-22
20-Aug-22
27-Aug-22
Daily Confirmed Cases
Confirmed Cases
-Sep-22
IndoVac
Recombinant COVID-19 Vaccine
Intramuscular Injection
10 VIALS
Discontinuation of Activity Restrictions (December 2022)
All provinces are at level 1;
■ Activity capacity 100%;
There are no more restrictions on operating hours.
No surge in COVID-19 Cases.
2.Vaccine Inavac
(Airlangga Univ and Biotis)
Full Report Fase I and Fase II have been submitted to FDA on
3rd August 2022 as base for EUA issuance
10-Sep-22
17-Sep-22
24-Sep-22
1-Oct-22
8-Oct-22
15-Oct-22
22-Oct-22
29-Oct-22
5-Nov-22
12-Nov-22
19-Nov-22
3-Dec-22
26-Nov-22
10-Dec-22
17-Dec-22
24-Dec-22
•
•
.
2022 Production: 10,5 million doses
.
2023 Production: 40 million doses
Emergency Use Listing (EUL): will be submit to WHO for
export purposes
On Progress: EUA for booster (adult) heterologous, clinical
trial for teenager and children
5View entire presentation